IMP321 (a sLAG-3-Ig agent) was the first LAG-3 based molecule in clinical trials and has been combined with vaccination and chemotherapy strategies to try and elicit anti-tumor responses as an apparent immune agonist [46,47]. This evidence concerns the gene LAG3 and neoplasm.